ArticlePloS one2013
High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 59 citations in OpenAlex.
- Dose-dependent effects of eltrombopag iron chelation on platelet formation.Blood vessels, thrombosis & hemostasis · 2025Article
- Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.BMC cancer · 2023Article
- Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.International journal of molecular sciences · 2021Review
- Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and plateletsHaematologica · 2021Review
- A Review of Romiplostim Mechanism of Action and Clinical Applicability.Drug design, development and therapy · 2021Review
- Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.Blood · 2020Review
- Induction of differentiation of human stem cellsWorld journal of stem cells · 2019Review
- Developmental differences between newborn and adult mice in response to romiplostim.Platelets · 2018Article
- A novel mode of stimulating platelet formation activity in megakaryocytes with peanut skin extract.Journal of natural medicines · 2018Article
- A new path to platelet production through matrix sensing.Haematologica · 2017Article
- Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy.Drug design, development and therapy · 2017Review
- Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.Haematologica · 2016Article
- Eltrombopag, a potent stimulator of megakaryopoiesis.Haematologica · 2016Article
- Hyaluronan based hydrogels provide an improved model to study megakaryocyte-matrix interactions.Experimental cell research · 2016Article
- Article
- Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia.Journal of blood medicine · 2016Review
- Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.Haematologica · 2015Article
- The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control.Cellular and molecular life sciences : CMLS · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRomiplostim (AMG531) is a Thrombopoietin (TPO) receptor agonist with no homology with the endogenous TPO that has been used to treat patients affected by immune thrombocytopenia (ITP). Despite the use of TPO mimetics in the clinical practice, the mechanisms underlying their impact on megakaryocyte function is still unknown. METHODOLOGY/PRINCIPAL
findingsIn this project we took advantage of an in vitro human model, that we have established in our laboratory for long time to study megakaryocyte development from human cord blood-derived progenitor cells, and we demonstrated that increasing doses of AMG531 (100 to 2000 ng/mL) determine a progressive increase of megakaryocyte proliferation with a parallel decrease in megakaryocyte ploidy and capacity of extending proplatelets. Most importantly, these differences in megakaryocyte function seemed to be correlated to modulation of AKT phosphorylation. CONCLUSIONS/SIGNIFICANCE: Overall our results shed new light on the mechanisms and on the relevance of dosage related to AMG531 impact on megakaryocyte function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.